Original news and analysis on international IP policy
The European Union has filed a World Trade Organization dispute settlement complaint against China for unfair treatment of foreign intellectual property rights holders. The case follows a similar filing by the United States against China.
A report published today by the EU Intellectual Property Office (EUIPO) deplores rising volume of intellectual property rights infringement in both immaterial goods and digital content and warns against the economic effects for the Union.
Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization.
El “acceso a los recursos genéticos” y “la participación justa y equitativa de los beneficios que provienen de su utilización” han atribulado las trece Conferencias de las Partes del Convenio de las Naciones Unidas sobre la Diversidad Biológica(CDB), que entró en vigor en 1993. La expresión entre comillas se conoce por sus siglas en inglés como “ABS”. Es el tercer objetivo del Convenio, entrelazado con los primeros dos, que son la conservación y el uso sostenible. A pesar de 25 años de esfuerzos y una bioeconomía de casi un trillón de dólares, pocos son los contratos de acceso que han sido celebrados. De esos pocos, los beneficios monetarios son tan bajos que las partes contratantes (y otros actores) son reacias a divulgarlos, bajo la excusa de “confidencialidad por sensibilidades comerciales”. La ley brasileña de ABS de 2015, que entró en vigor el 6 de noviembre de 2017 por ejemplo, permite que las regalías de las ventas netas sean tan bajas como la décima parte de uno por ciento. En palabras de un erudito jurista, los Usuarios pagan “una miseria por la biodiversidad”.
MUNICH -- United States and Chinese patent practitioners this week called for considerations to change patent legislation and allow patenting algorithms in the future. They spoke at a 30 May conference of the European Patent Office in Munich on “Patenting Artificial Intelligence.”
The new Intellectual Property Policy of South Africa has now been posted to a government website.
Sophia, the well-known human-like robot who acquired citizenship in Saudi Arabia, was at the Artificial Intelligence for Good Global Summit which took place earlier this month in Geneva. Her creator, David Hanson, also CEO and founder of Hanson Robotics, gave an interview to Intellectual Property Watch's Catherine Saez and explained his philosophy about intellectual property, the needed spark of interest in human-like robots, data collection, and innovation.
Hanson is also lead designer and inventor of key technologies including Frubber nanotech, facial expressions and AI software. He is former Walt Disney Imagineering designer, and recipient of numerous awards. A video interview about Sophia is embedded in this text.
Next week, the World Trade Organization intellectual property committee is invited to discuss two distinct aspects of intellectual property protection. One group of countries is proposing to explore the value of IP and its role in improving lives in a persistent agenda item on IP and innovation. Another group of countries is pushing for a more recent agenda on IP and the public interest and next week is suggesting to discuss how to use competition laws against the abuse of IP rights.
Alongside next week’s World Trade Organization intellectual property committee meeting, Brazil, India, and South Africa are convening a workshop on the neighbouring World Health Organization's approach to substandard and falsified medicines.
The Medicines Patent Pool announced this week that its Board agreed on the extension of the MPP mandate to patented medicines on the World Health Organization Essential Medicines List. The decision follows an extensive feasibility study. During a side event held on the margins of the annual World Health Assembly, Patent Pool officials explained the findings of the study, while in the audience, a representative of the pharmaceutical industry suggested a cautious approach.